Baltimore City public health officials have issued an urgent public health advisory regarding an increasing threat from benzodiazepines detected within the local and regional illicit drug supply, complicating acute overdose management.
In Plain English: The Clinical Takeaway
- The Contamination Threat: Potent sedatives are frequently mixed into street drugs like fentanyl, cocaine, and gabapentin without the user’s knowledge, compounding overdose dangers.
- The Naloxone Limitation: Standard emergency reversal drugs like naloxone will successfully treat co-present opioids, but they will not counteract a benzodiazepine’s sedative properties.
Surge in Maryland Drug Supply Contamination
Between April and July 2026, public health testing revealed benzodiazepines in 31 drug samples across Maryland. This is more than twice as many as the 14 samples found during the same months in 2025. The contaminated samples originated from Baltimore City as well as Calvert, Charles, Frederick, and Talbot Counties, with Charles County recording the highest concentration of detections.
The street drug bromazolam, an illicit benzodiazepine, is tied to seizures and coma and is showing up with increasing frequency in the US illicit drug supply. #FakeXanax #MedTwitter https://t.co/XZPkZqZjEs
State surveillance programs identified four specific benzodiazepine compounds circulating in the regional supply: bromazolam, deschlorodemethyldiazepam, ethylbromazolam, and lorazepam. These substances vary greatly in potency and are often mixed with fentanyl, cocaine, and gabapentin. This polysubstance contamination heightens the risk of profound sedation, respiratory depression, and death.
| Monitoring Period | Total Benzodiazepine Samples Detected | Primary Geographic Concentration |
|---|---|---|
| April–July 2025 | 14 samples | Maryland |
| April–July 2026 | 31 samples | Maryland |
Cellular Mechanism and Emergency Response Complications
Functioning as central nervous system depressants, benzodiazepines are sedative medications designed to reduce brain and neural activity. Prescription options such as lorazepam, diazepam, and alprazolam are routinely utilized to manage seizure disorders, insomnia, and anxiety, whereas alternative formulations lacking U.S. medical authorization—frequently designated as “novel” or “designer” benzodiazepines—are additionally circulated within illicit markets.
When these sedatives are co-administered with opioids or other central nervous system depressants, they produce severe clinical presentations characterized by deep sedation, hypotension (low blood pressure), bradycardia (slow resting heart rate), or respiratory compromise. First responders face a hurdle: administering naloxone will reverse opioid toxicity, but it does not act on the benzodiazepine (GABA) receptor. Consequently, patients may remain heavily sedated or difficult to rouse even after their breathing is restored, requiring intensive airway management and supportive hospital care.
Harm Reduction and Surveillance Protocols Across Maryland
To combat this, community outreach teams and Opioid-Associated Disease Prevention and Outreach Programs (OADPOPs) are distributing naloxone and supplies. Through Maryland’s Rapid Analysis of Drugs (RAD) program, participants can submit routinely returned paraphernalia for analysis via the National Institute of Standards and Technology (NIST), supplying information on trends in the drug supply.
Public health agencies urge individuals never to use drugs alone and to utilize benzodiazepine test strips available through community organizations such as Behavioral Health Systems Baltimore. Community partners recommend placing unresponsive individuals in the recovery position on their side while monitoring breathing until emergency medical services arrive.
Contraindications & When to Consult a Doctor
Abrupt cessation or unmonitored withdrawal from benzodiazepine exposure can be life-threatening and can last from 24 hours to multiple weeks, necessitating urgent clinical intervention.
References
- Baltimore City public health officials. Public Health Advisory: Benzodiazepines in the Illicit Drug Supply. 2026.
- Maryland Department of Health. Rapid Analysis of Drugs (RAD) Surveillance Reports.
- Philadelphia Department of Public Health. Benzodiazepine Withdrawal Management Guidance.
- National Institute of Standards and Technology (NIST).
